Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineSHMLF 53 Days Sales Outstanding is 47.40 as of Dec. 2025, which is 4% below its 10-year median of 49.58. GuruFocus rates SHMLF with a GF Score™ of 53/100 and a GF Value™ of $11.86. The stock has 5 warning signs investors should review. Among 657 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 54.03% on this metric.
The historical rank and industry rank for SHL Telemedicine's Days Sales Outstanding or its related term are showing as below:
SHMLF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.62 Med: 49.58 Max: 54.22
Current: 49.91
During the past 13 years, SHL Telemedicine's highest Days Sales Outstanding was 54.22. The lowest was 29.62. And the median was 49.58.
SHMLF's Days Sales Outstanding is ranked worse than 54.03% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 45.88
vs SHMLF: 49.91
SHL Telemedicine's Days Sales Outstanding
declined
from Dec. 2024 (47.71) to Dec. 2025 (47.40).
SHL Telemedicine (OTCPK:SHMLF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
SHL Telemedicine Days Sales Outstanding Related Terms
SHL Telemedicine Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for SHL Telemedicine's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHMLF vs VEEV, BTSG, HQY: Days Sales Outstanding Comparison
For the Health Information Services subindustry, SHL Telemedicine's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's Days Sales Outstanding falls into.
SHL Telemedicine Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHL Telemedicine (SHMLF) has a Days Sales Outstanding of 47.40 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on SHL Telemedicine and its competitors. This is near median its historical median of 49.58. Over the past decade, SHL Telemedicine's Days Sales Outstanding has ranged from 29.62 to 54.22. According to the industry distribution chart, SHL Telemedicine ranks #355 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 54%.
Is SHL Telemedicine's Days Sales Outstanding too high?
SHL Telemedicine's current Days Sales Outstanding of 47.40 is near median its 10-year median of 49.58. Over the past 10 years, this metric has ranged from a low of 29.62 to a high of 54.22. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.88. SHL Telemedicine's value of 47.40 is 3.3% above this industry median. Based on the distribution chart, SHL Telemedicine ranks #355 out of 657 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, SHL Telemedicine has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Days Sales Outstanding compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #355 out of 657 companies for Days Sales Outstanding. This places SHL Telemedicine in the lower half of its industry. The industry median Days Sales Outstanding is 45.88. SHL Telemedicine's value of 47.40 is 3.3% above this benchmark. Historically, SHL Telemedicine's own Days Sales Outstanding has ranged from 29.62 to 54.22 over the past decade. While the company's 10-year median is 49.58 vs. the industry median of 45.88, SHL Telemedicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.88, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current Days Sales Outstanding of 47.40 is 3.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current Days Sales Outstanding is 47.40, which is near median its own 10-year median of 49.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current Days Sales Outstanding of 47.40. The stock's GF Value™ is $11.86, compared to a current price of $4.84 — trading 59.2% below its estimated fair value. The current Days Sales Outstanding is 47.40, which is near median its 10-year median of 49.58 and 3.3% above the Healthcare Providers & Services industry median of 45.88. SHL Telemedicine's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current Days Sales Outstanding is 47.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.2% below its estimated GF Value™ of $11.86.
Key valuation signals for SHMLF:
Days Sales Outstanding: 47.40 (near median its 10-year median of 49.58)
GF Value™: $11.86 vs. price of $4.84 (59.2% below fair value)
Industry Position: 3.3% above the Healthcare Providers & Services median (#355 of 657)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
53GF Score
Get the complete analysis for SHMLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
